Ligand id: 7434

Name: budesonide

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: budesonide

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 6
Hydrogen bond donors 2
Rotatable bonds 4
Topological polar surface area 93.06
Molecular weight 430.24
XLogP 1.91
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Used by inhalation to treat asthma and severe chronic obstructive pulmonary disease (COPD). EMA approvals (2014) are for products containing budesonide and formoterol. May be used to treat Crohn's disease (inflammatory bowel disease) [3], inflammatory skin disorders, allergic rhinitis and in an extended release formulation, ulcerative colitis [1]. Symbicort® inhalers contain a fixed-dose formualtion of budesonide and the β2-adrenoceptor bronchodilator formoterol.
Oral formulations of this drug have EMA orphan disease approval to treat graft-versus-host disease (2006) and eosinophilic oesophagitis (2013).
In October 2014, the US FDA approved a rectal foam formulation containing budesonide (Uceris®) for the treatment of ulcerative colitis.
Mechanism Of Action and Pharmacodynamic Effects
Budesonide binds to the glucocorticoid receptor (GR) and the drug-receptor complex translocates to the nucleus and acts as transcription factor for target gene expression. The antiinflammatory actions of budesonide are thought to involve phospholipase A2 inhibitory proteins such as the annexins (aka lipocortins), which control the biosynthesis of the major mediators of inflammation, prostaglandins and leukotrienes. Increased expression of the gene coding for annexin-1 is one of the mechanisms by which glucocorticoids inhibit inflammation.
External links